The report provides comprehensive insights of the ongoing therapeutic research and development across Acne Vulgaris.
August 22, 2017 /MarketersMedia/ —
Acne Vulgaris -Pipeline Insights, 2017 report provides comprehensive insights of the ongoing therapeutic research and development across Acne Vulgaris. The report provides a complete understanding of the pipeline activities covering all clinical, pre-clinical and discovery stage products. A comparative pipeline therapeutics assessment of Acne Vulgaris by development stage, therapy type, route of administration and molecule type is also covered in the report. It also has a special feature on the inactive pipeline products in this area.
Request a demo of this research at https://www.diligentmarket.com/request-sample-page.php?gturl=11113>pname=Acne%20Vulgaris%20-%20Pipeline%20Insight,%202017
The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.
Companies discussed in this research are Allergan Pharma, Almirall, AndroScience Corporation, AntibioTx, AntiCancer, AOBiome, Arkin Dermatology, Basilea Pharmaceutica, Biomar Microbial Technologies, BioPharmX, Blueberry Therapeutics, Botanix Pharmaceuticals Ltd., Braintree Laboratories, Brickell Biotech Inc. and Cassiopea SpA.
Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases.
Scope of the report
• The report provides a snapshot of the pipeline development for the Acne Vulgaris
• The report covers pipeline activity across the complete product development cycle i.e. clinical, pre-clinical and discovery stages for the Acne Vulgaris
• The report provides pipeline product profiles which includes product description, developmental activities, licensors & collaborators and chemical information
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development, route of administration, and molecule type for Acne Vulgaris
• The report also covers the dormant and discontinued pipeline projects related to the Acne Vulgaris
Complete report of 90 pages is available at https://www.diligentmarket.com/acne-vulgaris-pipeline-insight-2017-11113-p.php
Reasons to Buy
• Establish comprehensive understanding of the pipeline activity across this Acne Vulgaris to formulate effective R&D strategies
• Gather information of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
• Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine
• Plot corrective measures for pipeline projects by understanding the pipeline depth and focus of Acne Vulgaris therapeutics
• Devise in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying inactive projects and understanding the factors that might have halted their progress
Table 1: Total Products for Acne Vulgaris
Table 2: Products in Clinical Stage
Table 3: Products in Pre-Clinical and Discovery Stage
Table 4: Assessment by Route of Administration
Table 5: Assessment by Stage and Route of Administration
Table 6: Assessment by Molecule Type
Table 7: Assessment by Stage and Molecule Type
Table 8: Inactive Products
Contact Info:
Name: Diane Conrad
Email: sales@diligentmarket.com
Organization: Diligent Market
Source URL: http://marketersmedia.com/global-acne-vulgaris-pipeline-insight-and-therapeutic-development-2017/231309
For more information, please visit https://www.diligentmarket.com/acne-vulgaris-pipeline-insight-2017-11113-p.php
Source: MarketersMedia
Release ID: 231309
